Patent ID: 11879008
Assignee: Q32 BIO INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating a complement mediated disease characterized by an increased deposition of C3d, the method comprising administering to a subject a fusion protein construct comprising:
(i) an antibody or an antigen-binding fragment thereof that specifically binds to a complement protein 3d (c3d), wherein the antibody or antigen-binding fragment thereof comprises;
(a) a heavy chain comprising three heavy chain complementarity determining regions (CDR-H1, CDR-H2, CDR-H3), wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 29, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 260, and the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 31, and
(b) a light chain comprising three light chain complementarity determining regions (CDR-L1, CDR-L2, CDR-L3), wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 32, the CDR-L2 comprises the amino acid sequence of SEQ ID NO: 33, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 34; and

(ii) a complement modulator polypeptide comprising a complement protein selected from the group consisting of: CR1, DAF, MCP, Crry, MAp44, MAp19, CD59, factor H, and a biologically active fragment thereof.